Treatment of Multiple Gingival Recession Defects Using a New Xenogenic Collagen Membrane Compared to Connective Tissue Graft: a Randomized Controlled Split-mouth Clinical Study

Mucogain Matrix Versus Connective Tissue Graft: "MUCOGREFFE Project"

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04800250

Acronym

Mucogreffe

Enrollment

Registered

2021-03-16

Start date

2023-07-24

Completion date

2026-05-26

Last updated

2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Recession

Brief summary

Limitation of donor site and significant postoperative morbidity are often described in connective tissue graft. We want to show if mucogain matrix used in tunnel technique to recover RTI Cairo recessions defects could be an alternative to connective tissue graft

Interventions

PROCEDURETreatment of gingival recessions

Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Case-control

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient with 3 contiguous, symmetrical and bilateral RTI Cairo gingival recessions (Miller Class 1) (i.e. 6 recessions) * Patient non-smoker * Patient affiliated to social security * Patient signed informed consent.

Exclusion criteria

* Patient with or having presented an acute or chronic severe cardiovascular, kidney, liver, gastrointestinal, allergic, endocrine, neuropsychiatric pathology, developed cancer of the upper aero digestive tract treated with radiotherapy * Patient with severe hemorrhinopathy * Patient treated with oral retinoids, bisphosphonates, oral or anticonvulsants * Patient who has taken steroidal or non-steroidal anti-inflammatory therapy, anti-cancer or immunosuppressive chemotherapy within the last 6 months. * Patient with contraindication to necessary and pre-, per- or post-operative treatments * Follow-up of the patient seemed difficult by the investigator * Patient with insufficient oral hygiene incompatible with oral surgery

Design outcomes

Primary

Measure	Time frame	Description
Mean root coverage obtained with both techniques	6 months	To compare the mean root coverage obtained with the Creos® Mucogain matrix and connective tissue graft in the treatment of Cairo RT1 class maxillary recessions (Miller Class 1).

Secondary

Measure	Time frame	Description
Postoperative pain with both techniques	6 months	To compare postoperative pain with both techniques
Postoperative complications with both techniques	10 days	To compare the occurrence of postoperative complications (haemorrhage, edema) within the first 10 days.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026